Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trial

• DOI: 10.1186/s12967-022-03859-w
• Publication Date: 2023-01-12T13:03:09Z
• Authors: Teng Ma; Rongrong Huang; Yanhua Xu; Yangbo Lv; Yifan Liu; Xin Pan; Jia Dong; Di Gao; Zeyu Wang; Fenglei Zhang; Chunxi Yan; Sang-Bing Ong; Yang Su; Dachun Xu
• Keywords: Clinical endpoint; GAS6

Abstract Background Growth arrest-specific 6 (GAS6) is a vitamin K-dependent protein related to inflammation, fibrosis, as well platelet function. Genetic ablation of GAS6 in mice protects against cardiac hypertrophy and dysfunction. Nonetheless, the association between plasma levels acute heart failure (AHF) patients still unknown. Methods We measured concentrations 1039 with AHF who were enrolled DRAGON-HF trial (NCT03727828). Mean follow-up study was 889 days. The primary endpoint all-cause death. Results In total, there 195 endpoints death 135 secondary cardiovascular during mean duration higher associated rates (P < 0.05). Baseline strongly correlated clinical outcomes different models after adjustment for factors N-terminal pro-brain natriuretic peptide (NT-proBNP, P could further distinguish risks based on NT-proBNP measurement. Conclusion Elevated an increased risk AHF. Trial registration NCT03727828 (DRAGON-HF trial) clinicaltrials.gov